These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 18663410)

  • 41. Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors.
    Ménard S; Casalini P; Tomasic G; Pilotti S; Cascinelli N; Bufalino R; Perrone F; Longhi C; Rilke F; Colnaghi MI
    Breast Cancer Res Treat; 1999 May; 55(2):169-77. PubMed ID: 10481944
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HER-2/neu as a predictive marker of response to breast cancer therapy.
    Pegram MD; Pauletti G; Slamon DJ
    Breast Cancer Res Treat; 1998; 52(1-3):65-77. PubMed ID: 10066073
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reporting results of cancer treatment.
    Miller AB; Hoogstraten B; Staquet M; Winkler A
    Cancer; 1981 Jan; 47(1):207-14. PubMed ID: 7459811
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
    Slamon DJ; Clark GM; Wong SG; Levin WJ; Ullrich A; McGuire WL
    Science; 1987 Jan; 235(4785):177-82. PubMed ID: 3798106
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
    McKeage K; Perry CM
    Drugs; 2002; 62(1):209-43. PubMed ID: 11790161
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
    Hortobagyi GN
    Semin Oncol; 2001 Dec; 28(6 Suppl 18):43-7. PubMed ID: 11774205
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic and predictive value of HER2/neu oncogene in breast cancer.
    Masood S; Bui MM
    Microsc Res Tech; 2002 Oct; 59(2):102-8. PubMed ID: 12373720
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy.
    Chorn N
    Oncol Nurs Forum; 2006 Nov; 33(2):265-72. PubMed ID: 16518442
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of HER2 status: for the treatment of metastatic breast cancers by humanized anti-HER2 Monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab).
    Umemura S; Sakamoto G; Sasano H; Tsuda H; Akiyama F; Kurosumi M; Tokuda Y; Watanabe T; Toi M; Hasegawa T; Osamura RY
    Breast Cancer; 2001; 8(4):316-20. PubMed ID: 11791124
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Development of HER2-specific humanized antibody Herceptin (trastuzumab)].
    Nihira S
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):504-14. PubMed ID: 14639005
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Her2 and trastuzumab in breast cancer.
    Horton J
    Cancer Control; 2001; 8(1):103-10. PubMed ID: 11176040
    [No Abstract]   [Full Text] [Related]  

  • 52. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
    Singer CF; Köstler WJ; Hudelist G
    Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Diagnosis of HER2 gene amplification in breast carcinoma].
    Couturier J; Vincent-Salomon A; Mathieu MC; Valent A; Bernheim A
    Pathol Biol (Paris); 2008 Sep; 56(6):375-9. PubMed ID: 18456424
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HER2/neu in the management of invasive breast cancer.
    Meric F; Hung MC; Hortobagyi GN; Hunt KK
    J Am Coll Surg; 2002 Apr; 194(4):488-501. PubMed ID: 11949754
    [No Abstract]   [Full Text] [Related]  

  • 56. Trastuzumab regimens for HER2-overexpressing metastatic breast cancer.
    Spigel DR; Burstein HJ
    Clin Breast Cancer; 2003 Dec; 4(5):329-37; discussion 338-9. PubMed ID: 14715107
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer.
    Gullo G; Bettio D; Torri V; Masci G; Salvini P; Santoro A
    Invest New Drugs; 2009 Apr; 27(2):179-83. PubMed ID: 18663410
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.
    Hanna WM; Rüschoff J; Bilous M; Coudry RA; Dowsett M; Osamura RY; Penault-Llorca F; van de Vijver M; Viale G
    Mod Pathol; 2014 Jan; 27(1):4-18. PubMed ID: 23807776
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.